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Abstract
Androgenetic alopecia is a condition mediated by androgen (specifically DHT) and
genetic factors causing hair loss and thinning of the scalp in men and women
Topical minoxidil (Rogaine) is the most commonly used medication for AGA that
stops hair loss and helps regrowth. However, it can cause an allergic reaction and its
efficacy relies on the patient’s compliance
Platelet-rich plasma injections for AGA is becoming more widespread as a safe, nonallergic alternative with little to no side effects

Results
•
Table 1. Comparison of study designs. PRP vs Minoxidil Monotherapy
Study

Design
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Introduction
Androgenetic alopecia is the most common form of alopecia, affecting up to 50% of
women and 80% of men during their lifetime
Women are affected the most following menopause
>50% of men over 50 have some degree of hair loss which increases in severity with
age
While considered a cosmetic concern, hair loss can pose a significant threat to a
person’s emotional and psychological wellbeing as well as their overall quality of life
Currently there is no cure and there are only two FDA approved treatment options
• Minoxidil is believed to stimulate hair growth by shortening the telogen
phase of the hair cycle and prolonging the anagen phase
• Finasteride treats AGA by regulating/inhibiting the production of an
androgen called dihydrotestosterone (DHT)
The efficacy of these 2 medications varies greatly amongst individuals, requires dailylifelong compliance, takes months to show noticeable results and can also be
associated with the unfortunate side effect of sexual dysfunction in men (oral
finasteride) as well as local irritation, allergic contact dermatitis and hypertrichosis
(topical minoxidil
PRP is an autologous concentration of platelets in plasma collected from the patient’s
own blood through centrifugation. The platelets are rich in growth factors which
promote hair growth by acting on stem cells of the hair follicles and stimulating
neovascularization
• If platelet-rich plasma (PRP) injections reduce hair loss and promote hair
regrowth more effectively in comparison to topical minoxidil

PRP Group Method

Minoxidil Group

PRP monotherapy; 18 cm3 of blood drawn,
sodium citrate anticoagulant, PRGF activator,
3-4 cm3 PRGF inj monthly x 2 months (2
sessions)
PRP monotherapy; 10 mL of blood drawn,
acid-citrate-dextrose anticoagulant, 5 mL PRP
inj biweekly x 8 weeks (4 sessions)

Topical minoxidil 3% QD x 4
months

Global photographs,
standardized trichograms

Topical minoxidil 2-5% x at
least 1 year

Global photographs,
standardized trichograms,
hair-pull test

PRP monotherapy; 25-35 mL of blood drawn,
sodium citrate anticoagulant, calcium
gluconate activator, 0.1-0.2 mL per inj
monthly x 4 months (4 sessions)

Topical minoxidil 5% BID x
6 months

Topical minoxidil 2% q12h x 6 months +
PRP; 10 mL of blood drawn, calcium chloride
activator, 1 mL inj q15d x 2 months then
monthly x 4 months (8 sessions)
Shah et
RCT
Total #: 50
6 months
Topical minoxidil 5% BID x 6 months + PRP
al.
50 men
w/ microneedling; 0.05 mL per inj monthly x
6 months (6 sessions)
Herakal
RCT
Total #: 50
18 months
PRP w/ microneedling; 10 mL of blood
et al.
50 men
drawn, inj twice per month x 6 months (12
sessions)
Key: RCT = randomized controlled trial; DLQI = dermatological life quality index

Topical minoxidil 2% q12h x
6 months

Global photographs, patient
standardized hair growth
questionnaire, patient
satisfaction score, hair-pull
test, platelet count
Global photographs, patient’s
self-assessment, physician’s
assessment, DLQI

Total #: 379
245 women
134 men

4 months

Starace
et al.

Not-randomized,
single group,
single-center
pilot study
RCT

Total #: 10
10 women

24 weeks
(6 months)

Total #: 30
30 men

6 months

RCT

Total #: 60
60 women

6 months

Vaaruni
et al.
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Topical minoxidil 5% BID x
6 months
Microneedling twice per
month + topical minoxidil 5%
QD x 6 months

Outcome Measure

•
•
•

Global photographs, patient’s
self-assessment, physician’s
assessment, platelet count
Global photographs,
standardized trichograms,
hair-pull test

Table 2. Validity assessment. PRP vs. Topical minoxidil
Study

Adequate timeline
(> 6 months)
M

Adequate Diversity
Intention to
Adequate PRP
Adequate Outcome
(inclusion of women)
Treat Analysis
Prep/Method
Measure/Reproducibility
Navarro et al.
A
A
A
A
(PRP
monotherapy)
Starace et al.
A
I
M
A
A
A
(PRP
monotherapy)
Verma et al.
A
I
I
A
A
A
(PRP
monotherapy)
Vaaruni et al.
A
A
M
A
A
M
(Topical
minoxidil 2% +
PRP)
Shah et al.
A
A
I
A
M
M
(Topical
minoxidil 5% +
PRP)
Herakal et al.
A
A
I
A
M
A
(PRP w/
microneedling)
Key: A = adequate, M = marginal, I = inadequate evidence
-Adequate PRP Prep/Method = Full description of volume of blood drawn, PRP anticoagulant/activator used, PRP volume injected, injection frequency & # of sessions
-Adequate Outcome Measure/Reproducibility = Global photography w/ reproducible technique, use of trichoscopic analysis and/or hair-pull test

Adequate Sample
Size (> 50)
A

Navarro et al.
(PRP monotherapy)
Starace et al.
(PRP monotherapy)
Verma et al.
(PRP monotherapy)
Vaaruni et al.
(Topical minoxidil 2% + PRP)
Shah et al.
(Topical minoxidil 5% + PRP)
Herakal et al.
(PRP w/ microneedling)

•
•
•
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Table 3. Summary of results. PRP vs. Topical minoxidil
Study

Methods
A literature search was performed in September 2019 via Google Scholar and Pubmed
using the terms "PRP" AND "minoxidil" AND "androgenetic alopecia". The search
was limited to articles published since 2015
Exclusion criteria: 1) Studies that included use of finasteride; 2) Studies that that were
specific to a racial or ethnic group; 3) Studies that included patients with alopecia other
than AGA such as alopecia areata, totalis, universalis, etc.
Inclusion criteria: 1) Studies that included both men and women; 2) Studies that
compared PRP and minoxidil as monotherapies rather than PRP as an adjuvant therapy

Duration

Retrospective
case control
study

Verma
et al.

•

Population

Navarro
et al.

Global Photography
Total
S

Global Photography
Volume/Density
S

Global Photography
Quantity
S

S

S

S

S

S

S

S

S

S

S

S

S

NS

NS

NS

Conclusion
Due to its autologous nature, PRP circumvents the side effects associated with
current FDA approved medications (minoxidil and finasteride)
PRP is a much easier treatment plan to adhere to; injections are once monthly and
are administered by a physician, PA or NP
Further research
• More studies are required to ascertain the optimal preparation and
injection methods
• Longer duration required to assess long-term progress
• Larger sample sizes for more accurate data
• Greater gender diversity as AGA affects women too
PRP is a safe alternative to topical minoxidil for the treatment of AGA in adults, but
may not be suitable for everyone
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Discussion
3 studies directly compared PRP monotherapy to topical minoxidil monotherapy
• Direct comparison; statistically significant
2 studies compared topical minoxidil in conjunction with PRP to topical minoxidil
monotherapy
• Indirect comparison; statistically significant
1 study compared PRP with microneedling to topical minoxidil with microneedling
• Direct comparison; statistically insignificant
Limitations
• Each study had varying methods of PRP preparation and injection
methods (volume of blood drawn, type of anticoagulant and activator,
minimum platelet count, injection depth & technique)
• Short duration of studies (studies ranged from 4 months to 18 months; 4
studies had a duration of 6 months)
• Small sample size (sample sizes ranged from 10 to 379; 4 studies had a
sample size of 50 or greater)
• Lack of gender diversity (3 studies had an all-male population; 2 studies
had an all-female population; only 1 study included both men and
women)
• Irreproducible global photography (lighting, angle and hair parting of
progress photos differed from baseline photos)
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